Non-small cell lung cancer-small cell lung cancer transformation as mechanism of resistance to tyrosine kinase inhibitors in lung cancer
The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping - Cancer Treatment Reviews
The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable - ScienceDirect
Capmatinib in MET Exon 14–Mutated or MET-Amplified Non–Small-Cell Lung Cancer | NEJM
Incidence and PD-L1 Expression of MET 14 Skipping in Chinese Populatio | OTT
Targeting MET in Cancer: Obstacles and Potentials | Insight Medical Publishing
Novel Therapies for Metastatic Non-Small Cell Lung Cancer with MET Exo | LCTT
Clinical analysis by next-generation sequencing for NSCLC patients with MET amplification resistant to osimertinib - Lung Cancer
Targeting MET in Lung Cancer: Will Expectations Finally Be MET? - Journal of Thoracic Oncology
MET/HGF pathway activation as a paradigm of resistance to targeted therapies - Ko - Annals of Translational Medicine
MET genetic lesions in non-small-cell lung cancer: pharmacological and clinical implications - Zorzetto - Translational Lung Cancer Research
MET amplification and epithelial-to-mesenchymal transition exist as parallel resistance mechanisms in erlotinib-resistant, EGFR -mutated, NSCLC HCC827 cells | Oncogenesis
Reciprocal relationship between MET amplification and T790M mutation.... | Download Scientific Diagram
BRAF V600E mutation and MET amplification as resistance pathways of the second-generation anaplastic lymphoma kinase (ALK) inhibitor alectinib in lung cancer - Lung Cancer
Targeting MET in Lung Cancer: Will Expectations Finally Be MET? - ScienceDirect
Reciprocal and Complementary Role of MET Amplification and EGFR T790M Mutation in Acquired Resistance to Kinase Inhibitors in Lung Cancer | Clinical Cancer Research
MET Signaling: Novel Targeted Inhibition and Its Clinical Development in Lung Cancer - Journal of Thoracic Oncology
The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping - Cancer Treatment Reviews
Tracking MET de-addiction in lung cancer: A road towards the oncogenic target - ScienceDirect
MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients - Annals of Oncology
MET Inhibition in Non-Small Cell Lung Cancer - European Medical Journal
MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer | Journal of Hematology & Oncology | Full Text
Targeting the MET Pathway for Lung Cancer Treatments, Biomarkers
new-molecular-drivers-in-nsclc-the-role-of-met
Introduction - Targeting METex14 NSCLC - Text Module - MET Inhibition in NSCLC - Oncology - Clinical Care Options
DISSECT platform with multi-omics data and various analytic tools - CNGBdb
FISH analysis of de novo MET amplification in advanced NSCLC and... | Download Scientific Diagram
